BusulfanArabinonucleosidesAdenine NucleotidesConsolidation ChemotherapyLeukemia, Myeloid, AcuteCytarabineMyeloablative AgonistsDeoxycytidine KinaseTransplantation ConditioningVidarabineAntineoplastic AgentsDrug Administration SchedulePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemiaHand-Foot SyndromeRemission InductionMyelodysplastic SyndromesCladribineBone Marrow TransplantationTreatment OutcomeAntineoplastic Agents, AlkylatingHepatic Veno-Occlusive DiseaseCyclophosphamideAntineoplastic Combined Chemotherapy ProtocolsInduction ChemotherapyMaximum Tolerated DoseLeukemia, MyeloidTransplantation, HomologousHematologic NeoplasmsRecurrenceInfusions, IntravenousIdarubicinGraft vs Host DiseaseWhole-Body IrradiationAlkylating AgentsSalvage TherapyTransplantation, AutologousAcute DiseaseDisease-Free Survivalfms-Like Tyrosine Kinase 3Immunosuppressive AgentsDose-Response Relationship, DrugMelphalanSurvival RateThiotepaAntimetabolites, AntineoplasticGraft SurvivalDrug MonitoringDrug Resistance, NeoplasmTime FactorsSulfonic AcidsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMolecular StructureSpermatogoniaHistocompatibilityTransplantation ChimeraOogoniaNeutropeniaCombined Modality TherapyAntilymphocyte SerumDrug SynergismPharmaceutical SolutionsSeminiferous Tubules